Executive Interview With Josh Phillipson Of Biondvax Pharmaceuticals

BiondVax's Josh Phillipson spoke with Edison TV about the company's M-001 Universal Flu Vaccine pivotal Phase 3 clinical trial

BiondVax Pharmaceuticals (Nasdaq: BVXV) is a clinical biopharmaceutical company developing a universal flu vaccine, known as M-001. M-001 is currently undergoing a pivotal, clinical efficacy, Phase III trial in about 12,400 participants, the results of which are expected by the end of 2020.

M-001 is designed to provide multi-season and multi-strain protection against all human influenza virus strains. In six completed clinical trials to date, the vaccine was shown to be safe, well tolerated and immunogenic to a broad range of flu strains.

Disclaimer: Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.